Stocktoria
BioXcel Therapeutics, Inc. BTAI
BioXcel Therapeutics, Inc. (BTAI) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $642,000 at a -10887.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -0.6 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BTAI | BioXcel Therapeutics, Inc. | 2/9 | — | — | — |
| VCNX | VACCINEX, INC. | 3/9 | — | — | — |
| ELAB | PMGC Holdings Inc. | 2/9 | — | — | — |
| LEXX | Lexaria Bioscience Corp. | 4/9 | — | — | — |
| VYNE | VYNE Therapeutics Inc. | 2/9 | — | — | — |
| SLN | Silence Therapeutics plc | 1/9 | -12.42 | — | -98.7% |
| QUCY | Quantum Cyber N.V. | 3/9 | — | — | — |
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
FAQ
Is BTAI financially healthy?
BioXcel Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does BTAI pay a dividend?
No, BioXcel Therapeutics, Inc. does not currently pay a dividend.
How profitable is BTAI?
In FY2025, BioXcel Therapeutics, Inc. had a net margin of -10887.4%.
What is the analyst price target for BTAI?
The average Wall-Street price target for BioXcel Therapeutics, Inc. is $14.00, about 1220.8% above the recent price, from 4 analysts.
Is BTAI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BioXcel Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.